title: Modulation of cisplatin chronotoxicity related to reduced glutathione in mice.
abstract: Intracellular reduced glutathione (GSH) concentrations were measured according to the tissue sampling-time along the 24 h scale in male B6D2F1 mice. A significant circadian rhythm in GSH content was statistically validated in liver, jejunum, colon and bone-marrow (P < or = 0.02) but not in kidney. Tissue GSH concentration increased in the dark-activity span and decreased in the light-rest span of mice. The minimum and maximum of tissue GSH content corresponded respectively to the maximum and minimum of cisplatin (CDDP) toxicity. The role of GSH rhythms with regard to CDDP toxicity was investigated, using a specific inhibitor of GSH biosynthesis, buthionine sulfoximine (BSO). Its effects were assessed on both tissue GSH levels and CDDP toxicity at three circadian times. BSO resulted in a 10-fold decrease of the 24 h-mean GSH in kidney. However a moderate GSH decrease characterized liver (-23%) and jejunum (-30%). BSO pretreatment largely enhanced CDDP toxicity which varied according to a circadian rhythm. Although BSO partly and/or totally abolished the tissue GSH rhythms, it did not modify those in CDDP toxicity. We conclude that GSH have an important influence on CDDP toxicity but not in the circadian mechanism of such platinum chronotoxicity.
authors.affiliation: Laboratoire Rythmes Biologiques et Chronothérapeutique Hôpital Paul Brousse, Villejuif, France.
authors.forename: N A
authors.initials: NA
authors.lastname: Boughattas
authors.forename: X M
authors.initials: XM
authors.lastname: Li
authors.forename: J
authors.initials: J
authors.lastname: Filipski
authors.forename: G
authors.initials: G
authors.lastname: Lemaigre
authors.forename: E
authors.initials: E
authors.lastname: Filipski
authors.forename: K
authors.initials: K
authors.lastname: Bouzouita
authors.forename: O
authors.initials: O
authors.lastname: Belhadj
authors.forename: F
authors.initials: F
authors.lastname: Lévi
mesh_terms: D000818:Animals; D000931:Antidotes / Q000032:analysis / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity*; D001772:Blood Cell Count / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D019328:Buthionine Sulfoximine / Q000494:pharmacology; D002940:Circadian Rhythm / Q000187:drug effects* / Q000502:physiology; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity*; D004064:Digestive System / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism* / Q000493:pharmacokinetics; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D015996:Survival Rate; D014018:Tissue Distribution
chemical_list: D000931:Antidotes; D000970:Antineoplastic Agents; D019328:Buthionine Sulfoximine; D005978:Glutathione; D002945:Cisplatin